UPBHIGH SIGNALFINANCIAL10-K

UPB reported positive Phase 2 trial results and advanced to Phase 3 planning, but burned through 69% of its cash reserves with R&D expenses more than doubling to $136.8M.

While the clinical progress is encouraging with positive results in both severe asthma and CRSwNP trials ahead of schedule, the dramatic cash burn rate raises immediate concerns about funding runway for the planned Phase 3 trials in 2027. The company will likely need additional financing soon, which could be dilutive to shareholders despite the positive clinical momentum.

Comparing 2026-03-26 vs 2025-03-12View on EDGAR →
FINANCIAL ANALYSIS

UPB's financials show a company aggressively investing in clinical development, with R&D expenses more than doubling to $136.8M, driving net losses to increase 128% to -$143.4M. The company's cash position deteriorated sharply from $325.9M to $101.6M (-68.8%), while operating cash outflows more than doubled to -$133.3M. This cash burn trajectory, combined with reduced stockholders' equity (-27.7%) and total assets (-26.6%), signals an urgent need for additional financing to fund the upcoming Phase 3 trials despite the promising clinical progress.

FINANCIAL STATEMENT CHANGES
Net Income
P&L
-128.4%
-$62.8M→-$143.4M

Net income declined 128.4% — review whether driven by operations, interest costs, or non-recurring items.

Operating Cash Flow
Cash Flow
-125.2%
-$59.2M→-$133.3M

Operating cash flow fell 125.2% — earnings quality concerns; investigate working capital changes and non-cash items.

R&D Expense
P&L
+117.3%
$63.0M→$136.8M

R&D investment increased 117.3% — signals commitment to future product development, though near-term margin impact.

Operating Income
P&L
-106.2%
-$77.8M→-$160.4M

Operating income deteriorated sharply — investigate whether driven by one-time charges or structural cost issues.

Cash & Equivalents
Balance Sheet
-68.8%
$325.9M→$101.6M

Cash declined 68.8% — significant cash burn or deployment; verify adequacy of remaining liquidity runway.

Capital Expenditure
Cash Flow
-67.7%
$511K→$165K

Capex reduced 67.7% — investment cycle winding down or capital discipline; may improve near-term free cash flow.

Stockholders Equity
Balance Sheet
-27.7%
$469.9M→$339.8M

Equity decreased 27.7% — buybacks or losses reducing book value, monitor solvency ratios.

Total Assets
Balance Sheet
-26.6%
$481.7M→$353.8M

Total assets contracted 26.6% — asset sales, write-downs, or balance sheet optimization underway.

Current Assets
Balance Sheet
-26.6%
$479.2M→$351.8M

Current assets declined 26.6% — monitor working capital adequacy and short-term liquidity.

Current Liabilities
Balance Sheet
+25.3%
$10.7M→$13.5M

Current liabilities rose 25.3% — increased short-term obligations, watch current ratio.

LANGUAGE CHANGES
NEW — 2026-03-26
PRIOR — 2025-03-12
ADDED
governmental agencies, new or increased tariffs and retaliatory tariffs, trade protection measures, economic sanctions and economic slowdowns or recessions, and inflation; our ability to attract, hire, and retain our key personnel and additional qualified personnel; our anticipated use of our existing cash, cash equivalents and short-term investments; our estimates regarding expenses, future revenue, capital requirements and needs for additional financing; and i other risks and uncertainties, including those listed under the caption Risk Factors.
We have advanced this highly potent monoclonal antibody into separate Phase 2 trials for the treatment of severe asthma, including a long-term safety and efficacy extension study ( Phase 2 LTE ), chronic rhinosinusitis with nasal polyps ( CRSwNP ), and chronic obstructive pulmonary disease ( COPD ).
We reported positive top-line results in our CRSwNP Phase 2 trial in September 2025 and positive top-line results in our severe asthma Phase 2 trial in February 2026.
We plan to initiate dosing in Phase 3 trials in both severe asthma and CRSwNP in the first quarter of 2027, prioritizing a Phase 3 development strategy that focuses on maximizing efficacy in both indications, without biomarker restriction, with quarterly at-home administration.
There are seven biologics approved for the treatment of severe asthma; four of these biologics are also approved for CRSwNP, and two are also approved for the treatment of COPD.
+7 more — sign up free →
REMOVED
We have advanced this highly potent monoclonal antibody into separate Phase 2 trials for the treatment of severe asthma and chronic rhinosinusitis with nasal polyps ( CRSwNP ) and have initiated planning activities for a Phase 2b trial in chronic obstructive pulmonary disease ( COPD ).
We completed enrollment in our CRSwNP Phase 2 clinical trial in January 2025 and expect to report top-line data from this trial in the second half of 2025, enabling regulatory discussions and preparations for a Phase 3 program in CRSwNP.
We anticipate reporting top-line data from our severe asthma Phase 2 trial in the second half of 2026 and plan to dose the first patient in our COPD program in the second half of 2025.
There are six biologics approved for the treatment of severe asthma; three of these are also approved for CRSwNP.
One biologic was recently approved for the treatment of COPD.
+7 more — sign up free →
MORE FINANCIAL SIGNALS
PNRGHIGHPNRG achieved exceptional profitability improvement with net income surging 2,21...
2026-04-16
BNAIHIGHBNAI underwent a dramatic reverse stock split that reduced share count by 86% wh...
2026-04-16
LAKEHIGHLAKE's financial performance deteriorated significantly with operating losses wo...
2026-04-16
NXXTHIGHNextNRG experienced massive financial deterioration with operating losses explod...
2026-04-16
ANALYZE ANY FILING FREE

See what changed in your portfolio's filings

500+ US-listed companies analyzed. Language delta, financial analysis, instant signal scoring.

Try Tracenotes free →